Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer.

Huo J, Ray-Zack MD, Shan Y, Chamie K, Boorjian SA, Kerr P, Jana B, Freedland SJ, Kamat AM, Mehta HB, Williams SB.

Eur Urol Oncol. 2019 Sep;2(5):497-504. doi: 10.1016/j.euo.2018.07.009. Epub 2018 Aug 17.

PMID:
31411998
2.

Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer.

Wang C, Raldow AC, Nickols NG, Nguyen PL, Spratt DE, Dess RT, Yu JB, King CR, Chu FI, Chamie K, Litwin MS, Saigal CS, Reiter RE, Liu ST, Rettig MB, Chang AJ, Steinberg ML, Kupelian PA, Kishan AU.

Eur Urol Oncol. 2019 Feb 1. pii: S2588-9311(19)30007-0. doi: 10.1016/j.euo.2019.01.006. [Epub ahead of print]

PMID:
31411981
3.

Predicting Short-term Outcomes After Radical Cystectomy Based on Frailty.

Michel J, Goel AN, Golla V, Lenis AT, Johnson DC, Chamie K, Litwin MS.

Urology. 2019 Jul 12. pii: S0090-4295(19)30610-7. doi: 10.1016/j.urology.2019.04.057. [Epub ahead of print]

PMID:
31306670
4.

Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer.

Williams SB, Hudgins HK, Ray-Zack MD, Chamie K, Smaldone MC, Boorjian SA, Daneshmand S, Black PC, Kamat AM, Goebell PJ, Seiler R, Schmitz-Drager B, Nawroth R, Baillargeon J, Klaassen Z, Kulkarni GS, Kim SP, Lee EK, Holzbeierlein JM, Hollenbeck BK, Gore JL.

Eur Urol Oncol. 2019 Mar;2(2):119-125. doi: 10.1016/j.euo.2018.07.006. Epub 2018 Aug 14.

PMID:
31017086
5.

Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus-Trends and effect on overall survival.

Lenis AT, Burton CS, Golla V, Pooli A, Faiena I, Johnson DC, Salmasi A, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K.

Urol Oncol. 2019 Sep;37(9):577.e9-577.e16. doi: 10.1016/j.urolonc.2019.03.009. Epub 2019 Mar 28.

PMID:
30930099
6.

Second primary lung cancer in United States Cancer Survivors, 1992-2008.

Donin NM, Kwan L, Lenis AT, Drakaki A, Chamie K.

Cancer Causes Control. 2019 May;30(5):465-475. doi: 10.1007/s10552-019-01161-7. Epub 2019 Mar 21.

PMID:
30900065
7.

Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma.

Faiena I, Astrow SH, Elashoff DA, Jain R, Bot A, Chamie K, Belldegrun AS, Pantuck AJ, Drakaki A.

Cancer Immunol Immunother. 2019 May;68(5):743-751. doi: 10.1007/s00262-019-02316-w. Epub 2019 Feb 21.

PMID:
30790015
8.

SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer.

Leow JJ, Bedke J, Chamie K, Collins JW, Daneshmand S, Grivas P, Heidenreich A, Messing EM, Royce TJ, Sankin AI, Schoenberg MP, Shipley WU, Villers A, Efstathiou JA, Bellmunt J, Stenzl A.

World J Urol. 2019 Jan;37(1):61-83. doi: 10.1007/s00345-018-2606-y. Epub 2019 Jan 25. Review.

PMID:
30684034
9.

Urinary Cytokine Profile to Predict Response to Intravesical BCG with or without HS-410 Therapy in Patients with Non-muscle-invasive Bladder Cancer.

Salmasi A, Elashoff DA, Guo R, Upfill-Brown A, Rosser CJ, Rose JM, Giffin LC, Gonzalez LE, Chamie K.

Cancer Epidemiol Biomarkers Prev. 2019 Jun;28(6):1036-1044. doi: 10.1158/1055-9965.EPI-18-0893. Epub 2018 Dec 28.

PMID:
30593457
10.

Diagnostic biomarkers in non-muscle invasive bladder cancer.

Faiena I, Rosser CJ, Chamie K, Furuya H.

World J Urol. 2018 Nov 22. doi: 10.1007/s00345-018-2567-1. [Epub ahead of print]

PMID:
30467596
11.

Variation in surgical treatment patterns for patients with prostate cancer in the United States: Do patients in academic hospitals fare better?

Pooli A, Salmasi A, Faiena I, Lenis AT, Johnson DC, Lebacle C, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K.

Urol Oncol. 2019 Jan;37(1):63-70. doi: 10.1016/j.urolonc.2018.10.018. Epub 2018 Nov 13.

PMID:
30446452
13.

Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients.

Williams SB, Kamat AM, Chamie K, Froehner M, Wirth MP, Wiklund PN, Black PC, Steinberg GD, Boorjian SA, Daneshmand S, Goebell PJ, Pohar KS, Shariat SF, Thalmann GN.

Eur Urol Oncol. 2018 Jun;1(2):91-100. doi: 10.1016/j.euo.2018.03.005. Epub 2018 Jun 6.

14.

Treatment utilization and overall survival in patients receiving radical nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma: evaluation of updated treatment guidelines.

Upfill-Brown A, Lenis AT, Faiena I, Salmasi AH, Johnson DC, Pooli A, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K.

World J Urol. 2019 Jun;37(6):1157-1164. doi: 10.1007/s00345-018-2506-1. Epub 2018 Sep 28.

PMID:
30267197
15.

Association between renal mass biopsy and upstaging to perinephric fat involvement in a contemporary cohort of patients with clinical T1a renal cell carcinoma.

Salmasi A, Faiena I, Lenis AT, Pooli A, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K.

Urol Oncol. 2018 Dec;36(12):527.e13-527.e19. doi: 10.1016/j.urolonc.2018.08.009. Epub 2018 Sep 15.

PMID:
30228094
16.

Radical prostatectomy then and now: Surgical overtreatment of prostate cancer is declining from 2009 to 2016 at a tertiary referral center.

Salmasi A, Faiena I, Wu J, Sisk AE Jr, Sachveda A, Vandel JJ, Chamie K, Marks LS, Reiter RE.

Urol Oncol. 2018 Sep;36(9):401.e19-401.e25. doi: 10.1016/j.urolonc.2018.06.006. Epub 2018 Jul 29.

PMID:
30064933
17.

Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapy.

Faiena I, Salmasi A, Mendhiratta N, Lenis AT, Pooli A, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K.

World J Urol. 2018 Nov;36(11):1825-1833. doi: 10.1007/s00345-018-2327-2. Epub 2018 May 11.

PMID:
29752514
18.

Association between Metabolic Syndrome and Recurrence of Nonmuscle Invasive Bladder Cancer following bacillus Calmette-Guérin Treatment.

Lenis AT, Asanad K, Blaibel M, Donin NM, Chamie K.

Urol Pract. 2018 Mar;5(2):132-138. doi: 10.1016/j.urpr.2017.02.012. Epub 2017 Mar 2.

19.

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.

Faiena I, Cummings AL, Crosetti AM, Pantuck AJ, Chamie K, Drakaki A.

Drug Des Devel Ther. 2018 Jan 23;12:209-215. doi: 10.2147/DDDT.S141491. eCollection 2018. Review.

20.

Trends in urinary diversion after radical cystectomy for urothelial carcinoma.

Bachour K, Faiena I, Salmasi A, Lenis AT, Johnson DC, Pooli A, Drakaki A, Pantuck AJ, Chamie K.

World J Urol. 2018 Mar;36(3):409-416. doi: 10.1007/s00345-017-2169-3. Epub 2018 Jan 3.

PMID:
29299664
21.

The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.

Liu ST, Hui G, Mathis C, Chamie K, Pantuck AJ, Drakaki A.

Clin Genitourin Cancer. 2018 Apr;16(2):e269-e276. doi: 10.1016/j.clgc.2017.10.011. Epub 2017 Nov 3. Review.

PMID:
29199023
22.

Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma.

Lenis AT, Salmasi AH, Donin NM, Faiena I, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Belldegrun AS, Pantuck AJ, Chamie K.

Urol Oncol. 2018 Feb;36(2):78.e21-78.e28. doi: 10.1016/j.urolonc.2017.09.030. Epub 2017 Nov 8.

PMID:
29128421
23.

Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection.

Faiena I, Salmasi A, Lenis AT, Donin NM, Johnson DC, Bachour K, Drakaki A, Belldegrun AS, Pantuck AJ, Chamie K.

Urol Oncol. 2018 Feb;36(2):79.e19-79.e26. doi: 10.1016/j.urolonc.2017.10.009. Epub 2017 Nov 2.

PMID:
29103965
24.

Role of surgical approach on lymph node dissection yield and survival in patients with upper tract urothelial carcinoma.

Lenis AT, Donin NM, Faiena I, Salmasi A, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Belldegrun A, Pantuck A, Chamie K.

Urol Oncol. 2018 Jan;36(1):9.e1-9.e9. doi: 10.1016/j.urolonc.2017.09.001. Epub 2017 Oct 20.

PMID:
29066013
25.

Increased Utilization of Positron Emission Tomography/Computed Tomography (PET/CT) Imaging and Its Economic Impact for Patients Diagnosed With Bladder Cancer.

Huo J, Chu Y, Chamie K, Smaldone MC, Boorjian SA, Baillargeon JG, Kuo YF, Kerr P, O'Malley P, Orihuela E, Tyler DS, Freedland SJ, Giordano SH, Vikram R, Kamat AM, Williams SB.

Clin Genitourin Cancer. 2017 Jul 26. pii: S1558-7673(17)30215-X. doi: 10.1016/j.clgc.2017.07.018. [Epub ahead of print]

26.

Trends in Aging-Related Services During Nephrectomy: Implications for Surgery in an Aging Population.

Tan HJ, Litwin MS, Chamie K, Saliba D, Hu JC.

J Am Geriatr Soc. 2017 Oct;65(10):2290-2296. doi: 10.1111/jgs.15046. Epub 2017 Aug 11.

27.

An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results.

Packiam VT, Lamm DL, Barocas DA, Trainer A, Fand B, Davis RL 3rd, Clark W, Kroeger M, Dumbadze I, Chamie K, Kader AK, Curran D, Gutheil J, Kuan A, Yeung AW, Steinberg GD.

Urol Oncol. 2018 Oct;36(10):440-447. doi: 10.1016/j.urolonc.2017.07.005. Epub 2017 Jul 26.

PMID:
28755959
28.

Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials.

Lenis AT, Donin NM, Johnson DC, Faiena I, Salmasi A, Drakaki A, Belldegrun A, Pantuck A, Chamie K.

J Urol. 2018 Jan;199(1):43-52. doi: 10.1016/j.juro.2017.04.092. Epub 2017 May 4. Review.

29.

Population-based assessment of racial/ethnic differences in utilization of radical cystectomy for patients diagnosed with bladder cancer.

Williams SB, Huo J, Kosarek CD, Chamie K, Rogers SO Jr, Williams MA, Giordano SH, Kim SP, Kamat AM.

Cancer Causes Control. 2017 Jul;28(7):755-766. doi: 10.1007/s10552-017-0902-2. Epub 2017 May 5.

30.

A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer.

Donin NM, Chamie K, Lenis AT, Pantuck AJ, Reddy M, Kivlin D, Holldack J, Pozzi R, Hakim G, Karsh LI, Lamm DL, Belkoff LH, Belldegrun AS, Holden S, Shore N.

Urol Oncol. 2017 Feb;35(2):39.e1-39.e7. doi: 10.1016/j.urolonc.2016.09.006. Epub 2016 Oct 26.

PMID:
28341495
31.

Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data.

Williams SB, Huo J, Chamie K, Smaldone MC, Kosarek CD, Fang JE, Ynalvez LA, Kim SP, Hoffman KE, Giordano SH, Chapin BF.

Cancer. 2017 May 1;123(9):1617-1624. doi: 10.1002/cncr.30506. Epub 2017 Jan 18.

32.

Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: Safety and feasibility.

Donin NM, Strauss-Ayali D, Agmon-Gerstein Y, Malchi N, Lenis AT, Holden S, Pantuck AJ, Belldegrun AS, Chamie K.

Urol Oncol. 2017 May;35(5):272-278. doi: 10.1016/j.urolonc.2016.11.019. Epub 2017 Jan 3.

PMID:
28065395
33.

Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer.

Miller ET, Chamie K, Kwan L, Lewis MS, Knudsen BS, Garraway IP.

Cancer Med. 2017 Jan;6(1):163-172. doi: 10.1002/cam4.981. Epub 2016 Dec 20.

34.

Patient Function and the Value of Surgical Care for Kidney Cancer.

Tan HJ, Shirk JD, Chamie K, Litwin MS, Hu JC.

J Urol. 2017 May;197(5):1200-1207. doi: 10.1016/j.juro.2016.12.012. Epub 2016 Dec 13.

PMID:
27986531
35.

Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.

Zimmermann M, Wang SS, Zhang H, Lin TY, Malfatti M, Haack K, Ognibene T, Yang H, Airhart S, Turteltaub KW, Cimino GD, Tepper CG, Drakaki A, Chamie K, de Vere White R, Pan CX, Henderson PT.

Mol Cancer Ther. 2017 Feb;16(2):376-387. doi: 10.1158/1535-7163.MCT-16-0381. Epub 2016 Nov 30.

36.

Regionalization of Cystectomy: Importance of Care Coordination, Bundled Payments and Surgical Ownership.

Lenis AT, Chamie K.

J Urol. 2017 Feb;197(2):278-279. doi: 10.1016/j.juro.2016.11.073. Epub 2016 Nov 11. No abstract available.

PMID:
27845149
37.

Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.

Chamie K, Donin NM, Klöpfer P, Bevan P, Fall B, Wilhelm O, Störkel S, Said J, Gambla M, Hawkins RE, Jankilevich G, Kapoor A, Kopyltsov E, Staehler M, Taari K, Wainstein AJA, Pantuck AJ, Belldegrun AS.

JAMA Oncol. 2017 Jul 1;3(7):913-920. doi: 10.1001/jamaoncol.2016.4419.

38.

Sustained-release Formulation of Mitomycin C to the Upper Urinary Tract Using a Thermosensitive Polymer: A Preclinical Study.

Donin NM, Duarte S, Lenis AT, Caliliw R, Torres C, Smithson A, Strauss-Ayali D, Agmon-Gerstein Y, Malchi N, Said J, Raman SS, Holden S, Pantuck A, Belldegrun AS, Chamie K.

Urology. 2017 Jan;99:270-277. doi: 10.1016/j.urology.2016.09.039. Epub 2016 Oct 5.

PMID:
27720772
39.

Racial Disparities in Active Surveillance for Prostate Cancer.

Krishna S, Fan Y, Jarosek S, Adejoro O, Chamie K, Konety B.

J Urol. 2017 Feb;197(2):342-349. doi: 10.1016/j.juro.2016.08.104. Epub 2016 Sep 3.

PMID:
27596691
40.

Risk of hospitalisation after primary treatment for prostate cancer.

Williams SB, Duan Z, Chamie K, Hoffman KE, Smith BD, Hu JC, Shah JB, Davis JW, Giordano SH.

BJU Int. 2017 Jul;120(1):48-55. doi: 10.1111/bju.13647. Epub 2016 Sep 16.

41.

Patient function, long-term survival, and use of surgery in patients with kidney cancer.

Tan HJ, Chamie K, Daskivich TJ, Litwin MS, Hu JC.

Cancer. 2016 Dec 15;122(24):3776-3784. doi: 10.1002/cncr.30275. Epub 2016 Aug 12.

42.

Immunotherapy for the Treatment of Urothelial Carcinoma.

Donin NM, Lenis AT, Holden S, Drakaki A, Pantuck A, Belldegrun A, Chamie K.

J Urol. 2017 Jan;197(1):14-22. doi: 10.1016/j.juro.2016.02.3005. Epub 2016 Jul 25. Review.

PMID:
27460757
43.

Association Between Number of Endoscopic Resections and Utilization of Bacillus Calmette-Guérin Therapy for Patients With High-Grade, Non-Muscle-Invasive Bladder Cancer.

Lenis AT, Donin NM, Litwin MS, Saigal CS, Lai J, Hanley JM, Konety BR, Chamie K; Urologic Diseases in America Project.

Clin Genitourin Cancer. 2017 Feb;15(1):e25-e31. doi: 10.1016/j.clgc.2016.06.014. Epub 2016 Jun 25.

44.

Body Mass Index and Survival in a Prospective Randomized Trial of Localized High-Risk Renal Cell Carcinoma.

Donin NM, Pantuck A, Klöpfer P, Bevan P, Fall B, Said J, Belldegrun AS, Chamie K.

Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1326-32. doi: 10.1158/1055-9965.EPI-16-0226. Epub 2016 Jul 14.

45.

Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008.

Donin N, Filson C, Drakaki A, Tan HJ, Castillo A, Kwan L, Litwin M, Chamie K.

Cancer. 2016 Oct;122(19):3075-86. doi: 10.1002/cncr.30164. Epub 2016 Jul 5.

46.

Determinants of radical cystectomy operative time.

Filson CP, Tan HJ, Chamie K, Laviana AA, Hu JC.

Urol Oncol. 2016 Oct;34(10):431.e17-24. doi: 10.1016/j.urolonc.2016.05.006. Epub 2016 Jun 29.

PMID:
27372282
47.

Underutilization of Radical Cystectomy Among Patients Diagnosed with Clinical Stage T2 Muscle-invasive Bladder Cancer.

Williams SB, Huo J, Chamie K, Hu JC, Giordano SH, Hoffman KE, Dinney CPN, Kamat AM, Shih YT.

Eur Urol Focus. 2017 Apr;3(2-3):258-264. doi: 10.1016/j.euf.2016.04.008. Epub 2016 May 13.

PMID:
28753760
48.

Population-based assessment of determining predictors for quality of prostate cancer surveillance.

Chamie K, Williams SB, Hershman DL, Wright JD, Nguyen PL, Hu JC.

Cancer. 2015 Dec 1;121(23):4150-7. doi: 10.1002/cncr.29574. Epub 2015 Aug 26.

49.

Population-Based Assessment of Determining Treatments for Prostate Cancer.

Chamie K, Williams SB, Hu JC.

JAMA Oncol. 2015 Apr;1(1):60-7. doi: 10.1001/jamaoncol.2014.192.

PMID:
26182305
50.

Watchful Waiting-Active Surveillance in Low-Risk Prostate Cancer-Reply.

Williams SB, Chamie K, Hu JC.

JAMA Oncol. 2015 Aug;1(5):689-90. doi: 10.1001/jamaoncol.2015.1199. No abstract available.

PMID:
26181144

Supplemental Content

Loading ...
Support Center